Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Corticorelin ovine triflutate
Drug ID BADD_D00530
Description Corticorelin, available commercially as corticorelin ovine triflutate (tradename Acthrel), is a synthetic form of the peptide human corticotropin-releasing hormone (hCRH), a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the pituitary to release ACTH. It is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion. It provides a differential diagnosis for Cushing's disease (a pituitary source of ACTH excess) or of ectopic ACTH syndrome (an ectopic source of ACTH excess). If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed with Cushing's disease. However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient is diagnosed with ectopic ACTH syndrome.
Indications and Usage Corticorelin is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB09067
KEGG ID D03592
MeSH ID C085671
PubChem ID 16132344
TTD Drug ID Not Available
NDC Product Code 52416-102
UNII 56X54T817Q
Synonyms corticorelin ovine | corticorelin ovine triflutate | Acthrel
Chemical Information
Molecular Formula C205H339N59O63S
CAS Registry Number 79804-71-0
SMILES CCC(C)C(C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C (=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CN=CN2)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC NC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C CSC)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)N)C(=O) NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(C)C(=O)NC(CC3=CN=C N3)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C( =O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)N)NC(=O)C4CCCN4C(=O)C 5CCCN5C(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CO)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood pressure ambulatory decreased13.14.03.017---
Blood pressure decreased13.14.03.002---
Cardiac arrest02.03.04.001--
Chest crushing12.01.18.001---
Drug interaction08.06.03.001---
Dyspnoea02.11.05.003; 22.02.01.004--
Endocrine disorder05.09.01.001---
Epilepsy17.12.03.002---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Heart rate decreased13.14.04.001---
Hyperventilation19.01.02.004; 22.02.01.006---
Hypotension24.06.03.002--
Loss of consciousness17.02.04.004---
Respiratory depth increased22.02.01.022---
Secondary adrenocortical insufficiency05.03.04.012; 14.11.01.014---
Tachycardia02.03.02.007---
Muscle tightness15.05.03.007---
Foetal heart rate decreased13.21.01.003---
The 1th Page    1    Total 1 Pages